50 Years of thiazides: Should thiazide diuretics be considered third-line hypertension treatment?

American Journal of Therapeutics

Volumn 18, Issue 6, 2011, Pages

  Brown, Angela ^a   Captain, Becky ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cardiovascular Consultants Inc   (United States)

Author keywords

antihypertensive therapy; combination therapy; hypertension; thiazide diuretics

Indexed keywords

ALISKIREN; AMLODIPINE; ATENOLOL; BENZODIAZEPINE; BISOPROLOL; CANDESARTAN; CARVEDILOL; CHLOROTHIAZIDE; CHLORTALIDONE; DIHYDROPYRIDINE; EPLERENONE; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; NEBIVOLOL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; OLMESARTAN; PROPRANOLOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; DRUG COST; DRUG SAFETY; HEART FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RENIN; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 81755188496     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181e90863     Document Type: Article

References (100)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
2. Tozawa M, Iseki K, Iseki C, et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41:1341-1345. (Pubitemid 36706087)
3. National Center for Health Statistics. Health, United States, 2008 With Chartbook. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; Library of Congress Catalog No. 76-641496. 2009.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
5. Whitworth JA. 2003 World Health Organization (WHO)/International Society ofHypertension (ISH) statement on management of hypertension. J Hypertens. 2003; 21:1983-1992. (Pubitemid 38296854)
6. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788. (Pubitemid 46842793)
7. Izzo R, de Simone G, Chinali M, et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009;32:845-850.
8. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913. (Pubitemid 35472129)
9. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.
10. Beyer KH. Chlorothiazide. Br J Clin Pharmacol. 1982;13: 15-24.
11. Smirk H, Mc QE, Morrison RB. Chlorothiazide and hydrochlorothiazide in management of hypertension. BMJ. 1960;1:515-518.
12. ALLHAT Investigator Group. Major outcomes in highrisk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
13. Austin PC, Mamdani MM, Tu K, et al. Changes in prescribing patterns following publication of the ALLHAT trial. JAMA. 2004;291:44-45. (Pubitemid 38040531)
14. US Food and Drug Administration.Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. US Food and Drug Administration, US Department of Health & Human Services. Available at:http://www.accessdata. fda.gov/Scripts/cder/ob/default.cfm. Accessed January 18, 2010.
15. Miller AB. Aldosterone antagonism in heart failure. Vasc Health Risk Manag. 2007;3:605-609. (Pubitemid 350104115)
16. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol. 2007;88:683-692.
17. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl). 1995;108:710-717.
18. Greenberg A. Diuretic complications. Am J Med Sci. 2000; 319:10-24. (Pubitemid 30367871)
19. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217-226. (Pubitemid 44885684)
20. Verdecchia P, Angeli F, Reboldi GP, et al. New-onset diabetes in treated hypertensive patients. Curr Hypertens Rep. 2005;7:174-179. (Pubitemid 40894922)
21. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48:219-224. (Pubitemid 44309815)
22. Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation. 2009;119:371-373.
23. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212-216. (Pubitemid 27339586)
24. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
25. Leren P, Helgeland A. Coronary heart disease and treatment of hypertension. Some Oslo Study data. Am J Med. 1986;80:3-6. (Pubitemid 16131296)
26. Barzilay JI,Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191-2201. (Pubitemid 44748765)
27. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832-842.
28. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:4-9. (Pubitemid 38031903)
29. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
30. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-921. (Pubitemid 23086643)
31. Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation. 2008;118:1383-1393.
32. Turner ST, Bailey KR, Fridley BL, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008;52:359-365.
33. Chapman AB, Schwartz GL, Boerwinkle E, et al. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002;61:1047-1055. (Pubitemid 34175474)
34. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119:417-425.
35. Mizgala HF. Newer drugs in the treatment of hypertension. Can Med Assoc J. 1965;92:918-922.
36. Hamer J, Grandjean T, Melendez L, et al. Effect of propranolol (Inderal) in angina pectoris: preliminary report. BMJ. 1964;2:720-723.
37. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207. (Pubitemid 46111014)
38. Cutler JA, Davis BR. Thiazide-type diuretics and betaadrenergic blockers as first-line drug treatments for hypertension. Circulation. 2008;117:2691-2704.
39. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366: 1545-1553. (Pubitemid 41540112)
40. Messerli FH, Beevers DG, Franklin SS, et al. Betablockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens. 2003;16:870-873. (Pubitemid 37204686)
41. Hart PD, Bakris GL. Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol. 2007;27:555-564. (Pubitemid 47381470)
42. Israili ZH, Lyoussi B, Hernandez-Hernandez R, et al. Metabolic syndrome: treatment of hypertensive patients. Am J Ther. 2007;14:386-402. (Pubitemid 47224822)
43. Nayler WG, Dillon JS. Calcium antagonists and their mode of action: an historical overview. Br J Clin Pharmacol. 1986;21(Suppl 2):S97-S107.
44. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005;46:637-642. (Pubitemid 43186729)
45. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;17:589-592.
46. US Food and Drug Administration. Drugs @ FDA. Center for Drug Evaluation and Research, US Food and Drug Administration, Department of Health and Human Services. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/ index.cfm; Keyword: Capoten. Accessed January 18, 2010.
47. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
48. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
49. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761-1769. (Pubitemid 37076361)
50. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359:995-1003. (Pubitemid 34286536)
51. Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997;30:140-145. (Pubitemid 27306360)
52. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
53. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48. (Pubitemid 351688350)
54. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462. (Pubitemid 23335891)
55. Jafar TH, Schmid CH, Landa M, et al. Angiotensinconverting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73-87. (Pubitemid 32661190)
56. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16: 592-599. (Pubitemid 41725095)
57. Azizi M, Menard J. Combined blockade of the renin- angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492-2499. (Pubitemid 38720545)
58. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006;1:221-228.
59. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-1163. (Pubitemid 46400330)
60. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190-198. (Pubitemid 351166266)
61. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-229. (Pubitemid 47069535)
62. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684-690. (Pubitemid 36999252)
63. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366: 895-906.
64. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:1755-1762. (Pubitemid 28269185)
65. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713-720.
66. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
67. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003; 21:1055-1076. (Pubitemid 36667856)
68. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens. 2008;21:493-499. (Pubitemid 351589673)
69. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3: 72-78. (Pubitemid 34966176)
70. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153-2164.
71. Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764. (Pubitemid 27387202)
72. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
73. Bellomo R, Prowle JR, Echeverri JE. Diuretic therapy in fluid-overloaded and heart failure patients. Contrib Nephrol. 2010;164:153-163.
74. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996;30:229-249.
75. Jamerson K,Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
76. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104: 2996-3007.
77. Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail. 1999;5: 184-185. (Pubitemid 29404119)
78. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658. (Pubitemid 32479962)
79. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994; 90:1765-1773.
80. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325: 293-302.
81. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821-828.
82. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333: 1670-1676. (Pubitemid 26001955)
83. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. (Pubitemid 33126822)
84. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
85. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003; 5:261-270. (Pubitemid 37011854)
86. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159-168. (Pubitemid 36044419)
87. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982; 247:1707-1714.
88. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
89. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390. (Pubitemid 32455364)
90. Pitt B, RemmeW, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
91. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153. (Pubitemid 30051645)
92. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592. (Pubitemid 36204952)
93. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289: 2073-2082. (Pubitemid 37430209)
94. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788. (Pubitemid 37093919)
95. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816. (Pubitemid 37509488)
96. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26:S80-82.
97. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
98. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349: 1857-1863.
99. Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636-1643. (Pubitemid 34765014)
100. Randomised trial of a perindopril-based blood-pressurelowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-1041.